期刊文献+

芪玉三龙方调节Wnt/β-catenin通路下游靶基因表达抑制荷瘤小鼠肺癌生长 被引量:10

Research on Qiyu Sanlong Formula inhibiting growth of tumor-bearing mice of lung cancer by regulating downstream target genes experession levels of Wnt/β-catenin signaling pathway
原文传递
导出
摘要 目的:探讨芪玉三龙方对荷肺癌小鼠的抑瘤效果和对Wnt/β-catenin信号通路下游靶基因c-myc、cyclin D1、Axin2表达的影响。方法:采用Lewis肺癌细胞株培养移植法建立肺癌荷瘤小鼠模型,随机分为模型组,芪玉三龙方低、中、高剂量组,化疗组,联合组,每组8只;造模第2天开始予以芪玉三龙方低、中、高剂量组小鼠分别按20.12、40.24、80.48g·kg-1·d-1灌胃给药,化疗组按照0.4m L顺铂腹腔注射给药,联合组以高剂量中药灌胃和顺铂腹腔注射联合给药,模型组按照等量0.9%氯化钠溶液给药,连续给药21d;称取瘤质量,计算抑瘤率;RT-q PCR检测肿瘤组织c-myc、cyclin D1、Axin2 m RNA的转录水平。结果:与模型组和低剂量组比较,芪玉三龙方中、高剂量组和化疗组c-myc m RNA表达显著降低(P<0.01)。与模型组比较,各用药组cyclin D1 m RNA表达显著降低(P<0.05,P<0.01);与低剂量组比较,中剂量组、化疗组表达显著降低(P<0.01)。与模型组比较,各用药组Axin2 m RNA表达显著降低(P<0.01);与低剂量组、化疗组比较,芪玉三龙方中、高剂量组表达显著降低(P<0.01)。结论:芪玉三龙方对肺癌移植瘤具有一定的抑制作用,其抑瘤机制可能与芪玉三龙方调节肺癌组织c-myc m RNA、cyclin D1 m RNA、Axin2 m RNA的转录水平有关。芪玉三龙方高剂量抑瘤效应较优,量效关系明显,其与化疗药合用具有协同效应。 Objective: To explore the antitumor effects of Qiyu Sanlong Formula on lung cancer mice. And the effects of TCM compounds Qiyu Sanlong Formula on the expression levels of the downstream target genes(c-myc, cyclin D1, Axin2) of Wnt/β-catenin signaling pathway were explored. Methods: Tumor-bearing mice model of lung cancer was established by using Lewis lung cancer cell line Then, mice were randomly divided into model group, chemotherapy group and Qiyu Sanlong Formula of high, middle, low dose group, and joint group, eight mice in each group. From the second day after molding, Qiyu Sanlong Formula of low, medium and high dose group were given 20.12, 40.24, 80.48 g·kg-1·d-1 by gavage respectively. Mice in chemotherapy group were given intraperitoneal injection of 0.4 m L cisplatin, mice in joint group were given high dose of TCM by gavage and intraperitoneal injection. Mice in model group were given the same amount of normal saline. These drugs were administrated for successive 21 days. The tumor mass and the tumor inhibition rate were calculated. The m RNA transcription levels of c-myc, cyclin D1, Axin2 in tumor tissues were detected by RT-q PCR. Results: Compared with model group and Qiyu Sanlong Formula of low dose group, Qiyu Sanlong Formula of middle, high dose group and chemotherapy group decreased significantly in c-myc m RNA(P〈0.01). Compared with model group, treatment groups decreased significantly in cyclin D1 m RNA(P〈0.05, P〈0.01). Compared with Qiyu Sanlong Formula of low dose group, middle dose group and chemotherapy group decreased significantly in cyclin D1 m RNA(P〈0.01). Compared with model group, the treatment groups decreased significantly in Axin2 m RNA(P〈0.01). Compared with low dose group and chemotherapy group, Qiyu Sanlong Formula of middle, high dose group decreased significantly in Axin2 m RNA(P〈0.01). Conclusion: Qiyu Sanlong Formula has certain inhibitory effect on transplantable lung cancer, and the anti-tumor mechanism might be related to the effect of Qiyu Sanlong Formula on regulating m RNA transcriptional levels of c-myc, cyclin D1, and Axin2 in lung cancer tissues. The high dose of Qiyu Sanlong Formula has a better antitumor effect and clear dose-effect relationship, and the combination treatment of Qiyu Sanlong Formula and chemotheraputic has synergistic effects.
作者 童佳兵 张星星 韩明向 李泽庚 TONG Jia-bing;ZHANG Xing-xing;HAN Ming-xiang;LI Ze-geng(The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei 230031;Anhui University of Chinese Medicine, Hefei 230012, China)
出处 《中华中医药杂志》 CAS CSCD 北大核心 2018年第5期2014-2017,共4页 China Journal of Traditional Chinese Medicine and Pharmacy
基金 安徽省自然科学基金项目(No.1708085MH197)~~
关键词 芪玉三龙方 肺癌 Wnt/β-catenin通路下游靶基因 C-MYC CYCLIND1 Axin2 Qiyu Sanlong Formula Lung cancer Downstream target genes of Wnt/β -catenin signaling pathway c-myc cyclinD 1 Axin2
  • 相关文献

参考文献9

二级参考文献110

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [J] . CACancer J Clin, 2012, 62(1) : 10-29.
  • 2Sandler A, Gray R,Perry MC,et al. Paclitaxel-carboplatin alone orwith bevacizumab for non-small-cell lung cancer[ J]. N En^ J Med,2006,355(24) : 2542 - 2450.
  • 3Li-Blatter X, Beck A, Seelig A- P-glycoprotein-ATPase modulation:the molecular mechanisms [J]. Biophys J, 2012,102 (6) : 1383 -1393.
  • 4Lee JJ, Maeng CH, Baek SK, et al. The immunohistochemical over-expression of ribonucleotide reductase regulatory subunit Ml(RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer(NSCLC) [J]. Lung Cancer, 2010,70(2) : 205 -210.
  • 5Yamaoka T, Ohmori T. The mechanisms of resistance to EGFR-TKIsand challenges to overcome resistance in EGFR mutant non-small celllung cancer[ J]. Gan To Kagaku Eyoho, 2012, 39(6) : 857 -862.
  • 6Papadaki C, Sfakianaki M, Ioannidis G, et al. ERCC1 and BRAC1mRNA expression levels in the primary tumor could predict the effec-tiveness of the second-line cisplatin-based chemotherapy in pretreatedpatients with metastatic non-small cell lung cancer [ J ]. J ThoracOncol, 2012, 7(4): 663 -671.
  • 7Fromowitz FB, Viola MV, Chao S, et al . ras p21 expression in theprogression of breast cancer[ J] . Hum Pathol, 1987,18( 12) : 1268-1275.
  • 8Kim KH, Do IG, Kim HS, et al. Excision repair cross-complementa-tion group 1 (ERCC1) expression in advanced urothelial carcinomapatients receiving cisplatin-basedchemolherapy [ J ]. APMIS, 2010,118(12) : 941 -948.
  • 9Chiu TJ, Chen CH, Chien CY, et al. High ERCC1 expressionpredicts cisplatin-based chemotherapy resistance and poor outcome inunresectable squamous cell carcinoma of head and neck in abetel-chewing area [J/OA]. J Transl Med, 2011,9: 31.
  • 10NCCN Clinical Practice Guidelines in Oncology for Non-Small CellLung Cancer. Version2. 2013 [ EB/OL]. http: //www. nccn. org/professionals/physician_ is/f_ guidelines, asp # site. Accessed : Jan21, 2013. [2013-01 -26].

共引文献79

同被引文献168

引证文献10

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部